Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Current Assets (2018 - 2025)

10x Genomics (TXG) has disclosed Current Assets for 8 consecutive years, with $684.5 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 17.12% to $684.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $684.5 million through Dec 2025, up 17.12% year-over-year, with the annual reading at $684.5 million for FY2025, 17.12% up from the prior year.
  • Current Assets hit $684.5 million in Q4 2025 for 10x Genomics, up from $659.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $757.2 million in Q2 2021 to a low of $562.3 million in Q3 2023.
  • Historically, Current Assets has averaged $643.5 million across 5 years, with a median of $632.2 million in 2022.
  • Biggest YoY gain for Current Assets was 73.53% in 2021; the steepest drop was 17.36% in 2021.
  • Year by year, Current Assets stood at $747.6 million in 2021, then decreased by 15.06% to $635.0 million in 2022, then dropped by 6.14% to $596.0 million in 2023, then decreased by 1.95% to $584.4 million in 2024, then rose by 17.12% to $684.5 million in 2025.
  • Business Quant data shows Current Assets for TXG at $684.5 million in Q4 2025, $659.8 million in Q3 2025, and $655.7 million in Q2 2025.